| Year |
Citation |
Score |
| 2022 |
Huang DB, Brothers KM, Mandell JB, Taguchi M, Alexander PG, Parker DM, Shinabarger D, Pillar C, Morrissey I, Hawser S, Ghahramani P, Dobbins D, Pachuda N, Montelaro R, Steckbeck JD, et al. Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug class. Plos One. 17: e0274815. PMID 36112657 DOI: 10.1371/journal.pone.0274815 |
0.578 |
|
| 2021 |
Huang D, Pachuda N, Sauer JM, Dobbins D, Steckbeck J. The Engineered Antibiotic Peptide PLG0206 Eliminates Biofilms and Is a Potential Treatment for Periprosthetic Joint Infections. Antibiotics (Basel, Switzerland). 11. PMID 35052918 DOI: 10.3390/antibiotics11010041 |
0.347 |
|
| 2020 |
Beumera JH, Guo J, Ray EC, Scemama J, Parise RA, Deslouches B, Steckbeck JD, Montelaro RC, Eiseman JL. Mass Balance Study of the Engineered Cationic Antimicrobial Peptide, WLBU2, Following a Single Intravenous Dose of 14C-WLBU2 in Mice. Current Clinical Pharmacology. PMID 32778037 DOI: 10.2174/1574884715666200810094201 |
0.75 |
|
| 2017 |
Hasek ML, Steckbeck JD, Deslouches B, Craigo JK, Montelaro RC. Engineered Cationic Antimicrobial Peptides Containing Cholesterol Interacting Motifs to Target Viral Envelopes Journal of Antivirals & Antiretrovirals. 9. DOI: 10.4172/1948-5964.1000158 |
0.776 |
|
| 2016 |
Deslouches B, Hasek ML, Craigo JK, Steckbeck JD, Montelaro RC. Comparative functional properties of engineered cationic antimicrobial peptides (eCAPs) consisting exclusively of tryptophan and either lysine or arginine. Journal of Medical Microbiology. PMID 27046192 DOI: 10.1099/Jmm.0.000258 |
0.751 |
|
| 2015 |
Abdelbaqi S, Deslouches B, Steckbeck J, Montelaro R, Reed DS. Novel engineered cationic antimicrobial peptides display broad-spectrum activity against Francisella tularensis, Yersinia pestis, and Burkholderia pseudomallei. Journal of Medical Microbiology. PMID 26673248 DOI: 10.1099/Jmm.0.000209 |
0.746 |
|
| 2015 |
Deslouches B, Steckbeck JD, Craigo JK, Doi Y, Burns JL, Montelaro RC. Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens. Antimicrobial Agents and Chemotherapy. 59: 1329-33. PMID 25421473 DOI: 10.1128/Aac.03937-14 |
0.743 |
|
| 2014 |
Kuhlmann AS, Steckbeck JD, Sturgeon TJ, Craigo JK, Montelaro RC. Unique functional properties of conserved arginine residues in the lentivirus lytic peptide domains of the C-terminal tail of HIV-1 gp41. The Journal of Biological Chemistry. 289: 7630-40. PMID 24497632 DOI: 10.1074/Jbc.M113.529339 |
0.611 |
|
| 2014 |
Steckbeck JD, Kuhlmann AS, Montelaro RC. Structural and functional comparisons of retroviral envelope protein C-terminal domains: still much to learn. Viruses. 6: 284-300. PMID 24441863 DOI: 10.3390/V6010284 |
0.563 |
|
| 2014 |
Steckbeck JD, Deslouches B, Montelaro RC. Antimicrobial peptides: new drugs for bad bugs? Expert Opinion On Biological Therapy. 14: 11-4. PMID 24206062 DOI: 10.1517/14712598.2013.844227 |
0.744 |
|
| 2013 |
Boscia AL, Akabori K, Benamram Z, Michel JA, Jablin MS, Steckbeck JD, Montelaro RC, Nagle JF, Tristram-Nagle S. Membrane structure correlates to function of LLP2 on the cytoplasmic tail of HIV-1 gp41 protein. Biophysical Journal. 105: 657-66. PMID 23931314 DOI: 10.1016/J.Bpj.2013.06.042 |
0.58 |
|
| 2013 |
Steckbeck JD, Sun C, Sturgeon TJ, Montelaro RC. Detailed topology mapping reveals substantial exposure of the "cytoplasmic" C-terminal tail (CTT) sequences in HIV-1 Env proteins at the cell surface. Plos One. 8: e65220. PMID 23724133 DOI: 10.1371/Journal.Pone.0065220 |
0.594 |
|
| 2013 |
Deslouches B, Steckbeck JD, Craigo JK, Doi Y, Mietzner TA, Montelaro RC. Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens. Antimicrobial Agents and Chemotherapy. 57: 2511-21. PMID 23507278 DOI: 10.1128/Aac.02218-12 |
0.76 |
|
| 2013 |
Steckbeck JD, Kuhlmann AS, Montelaro RC. C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic. The Journal of General Virology. 94: 1-19. PMID 23079381 DOI: 10.1099/Vir.0.046508-0 |
0.611 |
|
| 2013 |
Boscia AL, Akabori K, Benamram Z, Michel JA, Steckbeck JD, Jablin MS, Montelaro RC, Nagle JF, Tristram-Nagle S. LLP-2 Domain on the Cytoplasmic Terminal Tail (CTT) of HIV-1 GP41 affects T-Cell but not HIV Virion Membranes Biophysical Journal. 104: 247a. DOI: 10.1016/J.Bpj.2012.11.1389 |
0.58 |
|
| 2012 |
Gearhart T, Steckbeck JD, Craigo JK, Montelaro RC. Rate and affinity binding constants determined by SPR spectroscopy reveal differential antigenicity of HIV gp120 and gp140 Retrovirology. 9: 59. DOI: 10.1186/1742-4690-9-S2-P59 |
0.599 |
|
| 2012 |
Kuhlmann A, Steckbeck J, Sturgeon T, Craigo J, Montelaro R. The C-terminal tail of HIV-1 envelope: a unique role for conserved LLP arginines in Env functional properties Retrovirology. 9: 325. DOI: 10.1186/1742-4690-9-S2-P325 |
0.587 |
|
| 2012 |
Gearhart T, Steckbeck J, Montelaro R, Craigo J. Antigenicity of soluble HIV gp140 trimers reveals differences in solution conformation for differing HIV strains Retrovirology. 9: 313. DOI: 10.1186/1742-4690-9-S2-P313 |
0.614 |
|
| 2011 |
Steckbeck JD, Craigo JK, Barnes CO, Montelaro RC. Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: implications for functions in viral replication. The Journal of Biological Chemistry. 286: 27156-66. PMID 21659530 DOI: 10.1074/Jbc.M111.258855 |
0.595 |
|
| 2010 |
Steckbeck JD, Sun C, Sturgeon TJ, Montelaro RC. Topology of the C-terminal tail of HIV-1 gp41: differential exposure of the Kennedy epitope on cell and viral membranes. Plos One. 5: e15261. PMID 21151874 DOI: 10.1371/Journal.Pone.0015261 |
0.6 |
|
| 2010 |
Faith SA, Wu Y, Kuhrt D, Steckbeck JD, Craigo JK, Clements JE, Cole KS. Induction of antibody-mediated neutralization in SIVmac239 by a naturally acquired V3 mutation. Virology. 400: 86-92. PMID 20153009 DOI: 10.1016/J.Virol.2010.01.014 |
0.472 |
|
| 2010 |
Steckbeck JD, Sun C, Sturgeon TJ, Montelaro RC. Distinct Topologies For the HIV-1 Transmembrane Glycoprotein gp41 C-Terminal Tail on Cellular and Viral Lipid Membranes Biophysical Journal. 98: 49a. DOI: 10.1016/J.Bpj.2009.12.282 |
0.592 |
|
| 2009 |
Steckbeck JD, Sturgeon TJ, Sun C, Montelaro RC. P12-04. Topology of the C-terminal tail of HIV-1 gp41: Differential exposure of the Kennedy epitope on cell and viral membranes Retrovirology. 6. DOI: 10.1186/1742-4690-6-S3-P170 |
0.599 |
|
| 2008 |
Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. Plos One. 3: e1501. PMID 18231588 DOI: 10.1371/Journal.Pone.0001501 |
0.351 |
|
| 2007 |
Gupta S, Leutenegger CM, Dean GA, Steckbeck JD, Cole KS, Sparger EE. Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon. Journal of Virology. 81: 465-73. PMID 17079309 DOI: 10.1128/Jvi.00815-06 |
0.356 |
|
| 2006 |
Steckbeck JD, Cole KS. Dissecting the humoral immune response to simian immunodeficiency virus: mechanisms of antibody-mediated virus neutralization. Immunologic Research. 36: 51-60. PMID 17337766 DOI: 10.1385/Ir:36:1:51 |
0.421 |
|
| 2006 |
Steckbeck JD, Grieser HJ, Sturgeon T, Taber R, Chow A, Bruno J, Murphy-Corb M, Montelaro RC, Cole KS. Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance. Journal of Medical Primatology. 35: 248-60. PMID 16872288 DOI: 10.1111/J.1600-0684.2006.00173.X |
0.578 |
|
| 2005 |
Steckbeck JD, Orlov I, Chow A, Grieser H, Miller K, Bruno J, Robinson JE, Montelaro RC, Cole KS. Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strains. Journal of Virology. 79: 12311-20. PMID 16160158 DOI: 10.1128/Jvi.79.19.12311-12320.2005 |
0.613 |
|
| 2005 |
Craigo JK, Li F, Steckbeck JD, Durkin S, Howe L, Cook SJ, Issel C, Montelaro RC. Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy. Journal of Virology. 79: 2666-77. PMID 15708986 DOI: 10.1128/Jvi.79.5.2666-2677.2005 |
0.698 |
|
| 2004 |
Cole KS, Steckbeck JD, Rowles JL, Desrosiers RC, Montelaro RC. Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3. Journal of Virology. 78: 1525-39. PMID 14722307 DOI: 10.1128/Jvi.78.3.1525-1539.2004 |
0.732 |
|
| 2003 |
Li F, Craigo JK, Howe L, Steckbeck JD, Cook S, Issel C, Montelaro RC. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. Journal of Virology. 77: 7244-53. PMID 12805423 DOI: 10.1128/Jvi.77.13.7244-7253.2003 |
0.704 |
|
| 2003 |
Van Rompay KK, Greenier JL, Cole KS, Earl P, Moss B, Steckbeck JD, Pahar B, Rourke T, Montelaro RC, Canfield DR, Tarara RP, Miller C, McChesney MB, Marthas ML. Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. Journal of Virology. 77: 179-90. PMID 12477823 DOI: 10.1128/Jvi.77.1.179-190.2003 |
0.59 |
|
| 2002 |
Craigo JK, Leroux C, Howe L, Steckbeck JD, Cook SJ, Issel CJ, Montelaro RC. Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication. The Journal of General Virology. 83: 1353-9. PMID 12029150 DOI: 10.1099/0022-1317-83-6-1353 |
0.722 |
|
| Show low-probability matches. |